|Publication number||US4847049 A|
|Application number||US 07/028,645|
|Publication date||Jul 11, 1989|
|Filing date||Mar 20, 1987|
|Priority date||Dec 18, 1985|
|Publication number||028645, 07028645, US 4847049 A, US 4847049A, US-A-4847049, US4847049 A, US4847049A|
|Original Assignee||Vitaphore Corporation|
|Export Citation||BiBTeX, EndNote, RefMan|
|Patent Citations (19), Non-Patent Citations (4), Referenced by (213), Classifications (27), Legal Events (4)|
|External Links: USPTO, USPTO Assignment, Espacenet|
This is a continuation-in-part of Ser. No. 811,171 filed Dec. 18, 1985, now abandoned.
The present invention is directed to a method of producing silver-chelated collagen. In particular, the present invention provides a method for forming silver-chelated collagen for use in medical devices and therapeutic compositions.
Inherent in the use of medical devices, particularly in the use of devices which are at least in partial contact with body fluids, is the problem of infection. Furthermore, therapeutic uses of collagen, particularly for wound healing, repair of scar tissue, and cosmetic surgery, is becoming increasingly important. The problem with collagen, as with any other substance which is foreign to the body, is how to make these proteinaceous substances substantially sterile and/or inhibitive to infection. The present invention provides a method for producing antibacterial and antifungal collagen for such uses.
The type of collagen to which the present invention is applicable is insoluble, renatured collagen in the form of felts, foams, sponges, and films which are porous. By the term renatured, it is meant that the collagen is not collagen in its natural state, but rather it has been denatured to its triple helix form (often called tropocollagen or procollagen) by treatment of natural collagen with salt solutions, acid solutions and/or denaturing enzymes, then reprecipitated into collagen fibril. The fibrils are held together by bonding forces between the side chains of the amino acid residues of the protein chains, the main bond being hydrogen bonds. The association of fibrils into macromolecules, again by primarily hydrogen bonding, renatures, or reconstitutes, the collagen. The advantage of a renatured collagen is that, particularly in the case when denaturing enzymes are used, the renatured collagen is of much higher purity, being stripped of telopeptides and/or saccharides, thus resulting in collagen which is less antigenic than the naturally-occurring collagen. As used herein, the term renatured collagen also includes collagen which has been reconstituted to reform hydrogen bonding and chemically cross linked using chemical cross linking reagents such as, dialdehydes, diesters, diamines, and the like.
While treatment of some types of collagen with silver nitrate or other silver salts is known in the art (see Fox, et al., Ann. Chir. Plast., Vol. 24 (No. 3) pp. 265-267 (1979); and U.S. Pat. No. 4,294,241), it is believed that it has not been heretofore shown to improve collagen by forming a reconstituted and/or cross linked collagen having improved silver ion retention by treatment of ultraviolet radiation.
It is thus an object of the present invention to provide improved collagen having antibacterial and antifungal properties.
It is yet another object of the present invention to provide medical devices containing collagen on at least one surface thereof which has improved bactericidal and fungicidal properties.
It is yet another object of the present invention to provide topical therapeutic agents comprising collagen having improved antibacterial and antifungal properties.
Other objects and advantages of the present invention will be apparent from a further reading of the following specification and appended claims.
The present invention provides a method for protecting insoluble renatured collagen against bacterial and fungal attack comprising the steps of contacting the renatured collagen with silver ion-containing solution at a pH in the range from 4.0 to 9.0 to cause silver ions to be chelated to functional groups in the renatured collagen; and exposing the silver-chelated collagen to ultraviolet radiation of sufficient energy for a sufficient period of time to strengthen the binding of the silver ions to the renatured collagen without substantial formation of metallic silver or other oxidation products of silver (I).
In one preferred embodiment, the silver-chelating functional groups on the renatured collagen are increased by modifying the collagen by chemical means. The amino acid side chains in the collagen may be guanidated, modified by reaction with N-carboxy-amino acid anhydrides, or reacted with chondroiten sulfate. These modifying agents add additional sites for silver chelation, thereby enhancing the capacity of the collagen to retain silver.
In the accompanying drawings:
FIG. 1 is a plot of the size of the bactericidal zone versus pH in a Kirby-Bauer test of a composition according to the invention against E. coli.
FIG. 2 is a plot of results of a Kirby-Bauer test against K. pneumo.
FIG. 3 is a plot of results of a Kirby-Bauer test against S. aureus.
While exposure of natural collagen or gelatin to ultraviolet radiation in the presence of a photosensitive inorganic reagent, such as dichromate, hardens the gelatin or collagen by oxidation, this also consumes the dichromate, which is reduced. See Kosar, J. Light-Sensitive Systems, Wiley & Sons, New York, pp. 54-55 (1965); and U.S. Pat. No. 3,745,011 to Hudgin. While silver salts may also be utilized as photoinitiators in this way, the silver ion would also be consumed by a similar reaction by oxidation of functional chains in the proteins. However, according to the present invention, the consumption of the silver ion by oxidation upon exposure to ultraviolet light is to be avoided, since the object of exposure to ultraviolet light is not to oxidize and cross link the protein with a corresponding reduction of the silver ion, but rather to conserve the silver ion as a silver ion chelate for slow release into the environment, thus protecting the renatured collagen from fungal and bacterial attack for a prolonged period of time.
It has thus been surprisingly found that the exposure of a renatured collagen, and particularly, exposure of a covalently cross-linked renatured collagen, to ultraviolet radiation results in strengthening of the binding forces of the chelated silver ions to the collagen without substantial formation of metallic silver or other reduction products of silver (I).
A particularly advantageous result of the practice of the present invention is the increase of the silver binding capacity of the renatured collagen. As an example, in a typical renatured collagen sponge, the silver ion binding is increased up to about 50% when the silver ion is bound using the ultraviolet radiation according to the present invention. A typical result is the enhancement of the silver binding from 36.6 mg silver per gram collagen to 20.7 mg silver per gram collagen. Another particularly advantageous feature of the present invention is the increase of the period of time over which the silver retained in the collagen. When exposed to an aqueous environment, collagen impregnated with silver ion would leach the silver almost as rapidly as the salt is solubilized, therefore the rate of solubilization would be directly proportional to the degree to which the silver ion is bound to the collagen. In a typical example, in a stirred aqueous environment at pH 6 at 37° C., an ultraviolet-treated silver-collagen sponge made in accordance with the present invention loses 41.6% of its silver into the solution after 3 hours.
By comparison a similar silver-collagen sponge not treated with ultraviolet radiation loses 50.3% of its silver into the solution over that period of time.
A third particularly advantageous feature of the present invention is the relatively slow release of the silver ions into the aqueous environment. This is an advantage since too rapid a release of silver ions, which might occur if the silver ions were not tightly bound to the collagen, would also tend to irritate the surrounding tissues. Utilizing the silver-collagen made in accordance with the present invention, tissue irritation is thus minimized.
The collagen may be renatured to its insoluble form from natural sources such as bovine corium (hide), bovine tendon, and porcine skin. Preprocessed, insoluble collagen from animal sources is also commercially available as hemostatic agents under trade names such as Collastat™, Gelfoam™ sponge and Avitene™ nonwoven web. Methods of forming renatured collagen are known in the literature, including, for example, as described in U.S. Pat. Nos. 4,294,241 and 3,823,212.
A particularly preferred form of renatured collagen for utilization in accordance with the present invention is one which has been renatured and covalently cross-linked. This collagen may be prepared by utilizing readily available polyfunctional cross linking agents, such as dialdehydes, dicarboxylic acids, diamines, and the like. A typical procedure involves dissolving tropocollagen in a buffer of pH 3.0 to 5.0 wherein the solution contains approximately 1 to 2% by weight of the collagen. Then 1% of a dialdehyde cross-linking agent such as glutaraldehyde or formaldehyde is then added and the mixture frozen and stored for approximately 24 hours. After thawing and washing to remove unreacted cross linking agent, the renatured cross-linked collagen will be ready for contact with the silver ion-containing solution.
The source of silver ion may be a water soluble silver salt, preferably silver nitrate. While the concentration of the silver ion in the solution is not particularly critical, it will be usually convenient to utilize solutions in the concentration range of about 10 to 103 millimolar.
The renatured collagen will be contacted with a silver ion-containing solution in the pH range of about 4 to 9. The pH of the silver ion-containing solution will be controlled by the addition of an appropriate titrating agent, such as nitric acid, or potassium hydroxide, as required, to maintain the pH at less than about 9.0 to avoid the degradation of the silver. There is not believed to be any lower limit for the pH, however, normally a pH above 4.0 will be convenient. A particularly preferred range for the pH is from 7.0 to 7.5. The binding capacity of silver by collagen is particularly effective within this preferred pH range, although the amount of binding by silver by the collagen is further controllable by the concentration of the silver ion-containing solution and/or exposure time of the collagen to the silver ion-containing solution. Simultaneous with or subsequent to exposure of the collagen to the silver ion-containing solution, the collagen is then exposed to ultraviolet radiation of energy and duration sufficient to strengthen the binding of the silver ions to the collagen without substantial formation of metallic silver formed as a result of oxidation of various functional groups in the collagen by the silver ion. While the exact limits of the ranges of the conditions which will be sufficient to strengthen the binding of the silver ions without substantial formation of metallic silver are not precisely determinable, it will generally suffice to maintain the pH of the silver-collagen environment at less than 8.0 while exposing the collagen to ultraviolet radiation in the range of about 210 to 310 nm wavelength for about from 5 to 15 minutes. The time of UV exposure for complete reaction is inversely proportional to the light intensity which is preferably in the range of 100 to 1,000 microwatts/cm2. A slight coloration of the collagen due to the exposure to ultraviolet radiation is acceptable, i.e., a turning from white to a light brown to yellow color, indicating a slight oxidation reaction occurring in the collagen, however the radiation should not be to the extent that dark brown or black areas in the collagen occur due to overoxidation and/or substantial formation of metallic silver. Normally the exposure will be performed at ambient temperatures, i.e., in the range of about 20° to 25° C., however, there is not believed to be any reason why the exposure could not occur at higher or lower temperatures providing that the temperature is not high enough to cause degradation of the collagen and/or silver ion. There is not believed to be any lower limit to the temperature at which the exposure may take place, provided it is above the freezing point of the ion-containing solution.
Ultraviolet radiation may be provided by any conventional ultraviolet radiation source of appropriate wavelength, such as germicidal lamps and mercury/xenon lamps.
The renatured collagen prepared in accordance with the present invention is particularly useful in the preparation of medical devices to be used in contact with bodily fluids and tissues. Thus, such devices as sutures, wound dressings, and tissue ingrowth implant coatings which may contain collagen to assist in the healing process, may be made from the collagen provided in accordance with the present invention.
Other uses of the renatured collagen according to the present invention include uses in topical therapeutic compositions which contain collagen, such as collagen which is used in cosmetic surgery.
In another particularly preferred embodiment of the present invention, the number of functional groups in the collagen which are chelatable to silver ions is enhanced by reacting modifying agents which add functional groups with the collagen. While not intending to be bound by any particular theory, it is believed that the silver ion is primarily chelated in the collagen to amine groups, either from the free amino ends of the peptides or, primarily, from the nitrogen-containing side chains of the amino acids, lysine, hydroxylysine, asparagine, glutamine and arginine. This is suggested by an assay of free amines utilizing ortho-phthaldehyde fluorescence (by the technique described by Bensen, et al., Proc. Nat. Acad. Sci., Vol. 72 (No. 2), pp. 619-622 (1975)) of a renatured collagen versus a silver-chelated renatured collagen in accordance with the present invention which shows 86.9% reduction in ortho-phthaldehyde reactivity, indicating a corresponding reduction in the number of available amine groups due to chelation with the silver ions.
Thus, one method of enhancing the number of silver chelatable groups in the collagen is to guanidate the collagen utilizing known protein guanidation techniques. Guanidation converts the side chain of lysine residues into arginine residues which have twice the amine content, thus increasing silver binding capacity. Guanidation may be readily performed upon collagen, for example, by soaking in a 0.2 to 1 molar solution of o-methylisourea at a pH in the range of 10.2 to 11. Another method of guanidation is to treat the renatured collagen with GDMP (1-guanyl-3,5-dimethylpyrazole nitrate) at a concentration of 0.5 to 0.2 M at a pH of 9.5. It has been found that guanidation of renatured collagen increases the silver binding capacity by approximately 200 to 400%.
There are several other chelatable groups within the amino acids in collagen, such as the carboxyl groups of aspartate and glutamate. However, carboxyl groups in general do not bind as tightly to silver ions as amine groups. The sulfhydryl groups on the side chains of methionine and cysteine also tightly bind silver ions, although their occurrence in most collagen protein chains is less than that of amine groups. Due to the differences among the energies of chelation of silver ion with amine, carboxyl and sulfhydryl groups, the silver binding capacity and release characteristics of the particular collagen may be modified to meet desired medical applications. This may be done by adding amino acids to the collagen by use of activated amino acids such as N-carboxy-alpha amino acid anhydrides (NCAs) onto free amino groups on the protein chains within the collagen to form amide bonds. Thus treatment of the renatured collagen with arginine NCA would create additional amine binding sites, whereas treatment with cysteine would add sulfhydryl binding sites. Treatment of a collagen with aspartate or glutamate NCA would add carboxyl sites which have a lower chelation binding energy with silver than amines or sulfhydryl groups. By selection of the particular type of NCAs, the overall binding capacity and release characteristics of the collagen may be modified as desired, depending on the particular end use of the collagen.
A third method of modifying the collagen is to treat the collagen with chondroiten sulfate, a natural tissue proteoglycan found predominantly in cartilage. Chondroiten sulfate has a repeating disaccharide structure with ester sulfate groups pendent from the carbohydrate ring. The number of ester sulfates varies, with an average of about 0.8 sulfate groups per disaccharide. The binding of the chondroiten sulfate to the collagen is ionic in nature and may be accomplished by soaking the collagen in an aqueous solution of chondroiten sulfate of a concentration preferably in the range of 10 to 200 mg/ml at a pH of 2.5 to 4.5 for about 1 hour. The collagen is then washed and then soaked in an appropriate silver ion-containing solution whereby the ester sulfate groups, which chelate the silver ions, increase the total silver binding capacity of the collagen. A typical treatment may increase the silver binding capacity of a renatured collagen by 50%.
A particular use, as discussed above, for the collagen prepared according to the present invention, is as a medical device for contact with bodily fluids and tissues. The particularly preferred device for that application is a positionable tissue interfacing device for the management of percutaneous conduits, which is generally described for example, in commonly assigned U.S. Ser. No. 653,442 filed Sept. 21, 1984. The collagen components of such devices will comprise the tissue ingrowth material allowing the formation of a tissue seal without the risk of bacterial proliferation in the porous matrix.
Another use for the collagen in accordance with the present invention is as a wound healing and scar tissue concealing material for cosmetic surgery. Uses of collagen in this manner are per se known, however, the utilization of the collagen made according to the present invention reduces the chance and occurrence of infection at the wound and scar site.
Having described the preferred embodiments of the present invention, the following example is given to further illustrate the present invention. The scope of the invention is not to be limited by the specific details of the example.
A solution of 500 mls. of demineralized water containing 8.5 grams of silver nitrate is titrated to a pH between 7 to 7.5. To this solution 20 grams of collagen (commercially available from Sigma Chemical Co.) are placed while maintaining a temperature at 25° C. Mixing is continued for approximately 30 minutes. Also during this period of time, ultraviolet radiation from a mercury lamp is used to expose the solution.
The collagen is collected by filtration, washed and tested for bactericidal activity by the Kirby-Bauer swabbed plate method. Referring to the FIGURES, the results show the bactericidal activity as detected by this test on three plate transfers.
Referring to FIG. 1, there is shown a plot of the diameter of the zone size exhibiting antibacterial activity against E. coli. versus the pH of the Mueller-Hinton test medium used to swab a plate in the Kirby-Bauer test. The zone size increased (i.e., antibacterial activity increased) as pH increased or decreased from about pH 6.0-7.0. FIG. 2 is a plot of the same parameters in a test against K. pneumo. FIG. 3 is a plot of the same parameters in a test against S. aureus. These three microorganisms are commonly associated with clinical infections. The effect of enhancement of bactericidal activity with increasing acidity or basicity of the medium is advantageous, since the pH at a wound site will usually decrease as infection is resisted by local tissue defenses.
|Cited Patent||Filing date||Publication date||Applicant||Title|
|US2304478 *||Oct 19, 1939||Dec 8, 1942||Rosenzweig Salo||Process of treating materials comprising albumin, such as hair, bristles and the like|
|US3152976 *||Sep 21, 1961||Oct 13, 1964||Ethicon Inc||Preparation of collagenous materials|
|US3380848 *||May 27, 1964||Apr 30, 1968||Polymer Res Corp Of America||Method of producing solid polymeric material having bactericidal properties|
|US3427301 *||Apr 6, 1966||Feb 11, 1969||Us Agriculture||Crosslinking of collagens employing a redox system comprising persulphate and a reducing agent|
|US3748142 *||Oct 15, 1971||Jul 24, 1973||Avicon Inc||Photographic coatings containing a water insoluble ionizable partial salt of collagen|
|US3792161 *||Nov 24, 1970||Feb 12, 1974||Research Corp||Burn ointment comprising silver sulfadiazine and collagenase|
|US3800792 *||Apr 17, 1972||Apr 2, 1974||Johnson & Johnson||Laminated collagen film dressing|
|US4280954 *||Apr 16, 1979||Jul 28, 1981||Massachusetts Institute Of Technology||Crosslinked collagen-mucopolysaccharide composite materials|
|US4294241 *||Oct 19, 1979||Oct 13, 1981||Teruo Miyata||Collagen skin dressing|
|US4424188 *||Dec 31, 1981||Jan 3, 1984||International Paper Company||Sterilization of packaging material|
|US4446124 *||Mar 31, 1983||May 1, 1984||Fox Jr Charles L||Wound dressing comprising silver sulfadiazine incorporated in animal tissue|
|US4448718 *||Sep 13, 1983||May 15, 1984||Massachusetts Institute Of Technology||Method for the preparation of collagen-glycosaminoglycan composite materials|
|US4451397 *||Nov 22, 1982||May 29, 1984||Centre Technique Du Cuir||Method of preparing collagen products|
|US4488911 *||Sep 15, 1983||Dec 18, 1984||Luck Edward E||Non-antigenic collagen and articles of manufacture|
|US4505855 *||Sep 30, 1982||Mar 19, 1985||Massachusetts General Hospital||Transparent non-fibrilized collagen material by ultracentrifugation|
|US4581028 *||Apr 30, 1984||Apr 8, 1986||The Trustees Of Columbia University In The City Of New York||Infection-resistant materials and method of making same through use of sulfonamides|
|EP0099758A2 *||Jul 20, 1983||Feb 1, 1984||University of Strathclyde||Composite wound dressing|
|GB1588933A *||Title not available|
|GB2138302A *||Title not available|
|1||*||Fox et al., Ann. Chir. Plast., 24(3), 25 267.|
|2||Fox et al., Ann. Chir. Plast., 24(3), 25-267.|
|3||*||Light Sensitive Systems: pp. 16 21, 54 63 and 187, Kosar, published 1965.|
|4||Light-Sensitive Systems: pp. 16-21, 54-63 and 187, Kosar, published 1965.|
|Citing Patent||Filing date||Publication date||Applicant||Title|
|US5324275 *||Oct 2, 1992||Jun 28, 1994||Board Of Regeants, University Of Texas System||Antimicrobial medical devices|
|US5395651 *||Jun 10, 1992||Mar 7, 1995||Ad Tech Holdings Limited||Deposition of silver layer on nonconducting substrate|
|US5409467 *||Dec 28, 1993||Apr 25, 1995||Board Of Regents, The University Of Texas System||Antimicrobial catheter|
|US5554106 *||Oct 13, 1994||Sep 10, 1996||Quinton Instrument Company||Hydrocolloid exit site dressing|
|US5569207 *||Oct 13, 1994||Oct 29, 1996||Quinton Instrument Company||Hydrocolloid dressing|
|US5714582 *||Mar 17, 1995||Feb 3, 1998||Bioscience Consultants||Invertebrate type V telopeptide collagen, methods of making, and use thereof|
|US5747178 *||Mar 6, 1995||May 5, 1998||Adtech Holding||Deposition of silver layer on nonconducting substrate|
|US5814094 *||Mar 28, 1996||Sep 29, 1998||Becker; Robert O.||Iontopheretic system for stimulation of tissue healing and regeneration|
|US5833665 *||Jun 7, 1995||Nov 10, 1998||Integra Lifesciences I, Ltd.||Polyurethane-biopolymer composite|
|US5868778 *||May 5, 1997||Feb 9, 1999||Vascular Solutions, Inc.||Vascular sealing apparatus and method|
|US5957952 *||Mar 31, 1997||Sep 28, 1999||Vascular Solutions, Inc.||Vascular sealing device|
|US5965204 *||May 4, 1998||Oct 12, 1999||Ad Tech Holdings Limited||Deposition of silver layer on nonconducting substrate|
|US5972366 *||Sep 17, 1996||Oct 26, 1999||The Unites States Of America As Represented By The Secretary Of The Army||Drug releasing surgical implant or dressing material|
|US6013106 *||Jan 22, 1997||Jan 11, 2000||St. Jude Medical, Inc.||Medical article with adhered antimicrobial metal ions and related methods|
|US6017359 *||Jun 17, 1997||Jan 25, 2000||Vascular Solutions, Inc.||Vascular sealing apparatus|
|US6071447 *||Oct 8, 1997||Jun 6, 2000||Integra Lifescineces I, Ltd.||Method of making a polyurethane-biopolymer composite|
|US6153210 *||Aug 14, 1997||Nov 28, 2000||Periodontix, Inc.||Use of locally delivered metal ions for treatment of periodontal disease|
|US6165484 *||Aug 25, 1998||Dec 26, 2000||Wake Forest University||EDTA and other chelators with or without antifungal antimicrobial agents for the prevention and treatment of fungal infections|
|US6168580||Mar 26, 1999||Jan 2, 2001||Iontophoretics Corporation||Antimicrobial device and methods for long-term catheters|
|US6190407||Dec 31, 1998||Feb 20, 2001||St. Jude Medical, Inc.||Medical article with adhered antimicrobial metal|
|US6224983||Aug 13, 1999||May 1, 2001||Ad Tech Holdings Limited||Deposition of silver layer on nonconducting substrate|
|US6242009||Apr 20, 1999||Jun 5, 2001||Kareem I. Batarseh||Microbicidal formulations and methods to control microorganisms|
|US6267782||Aug 31, 1998||Jul 31, 2001||St. Jude Medical, Inc.||Medical article with adhered antimicrobial metal|
|US6296658||Jan 25, 2000||Oct 2, 2001||Vascular Solutions, Inc.||Vascular sealing apparatus|
|US6347241||Jun 30, 1999||Feb 12, 2002||Senorx, Inc.||Ultrasonic and x-ray detectable biopsy site marker and apparatus for applying it|
|US6427081||Sep 5, 2000||Jul 30, 2002||Senorx, Inc.||Methods and chemical preparations for time-limited marking of biopsy sites|
|US6497706||Nov 16, 2000||Dec 24, 2002||Senorx, Inc.||Biopsy device and method of use|
|US6509319||Oct 4, 2000||Jan 21, 2003||Board Of Regents, The University Of Texas System||EDTA and other chelators with or without antifungal antimicrobial agents for the prevention and treatment of fungal infections|
|US6540695||Dec 28, 2000||Apr 1, 2003||Senorx, Inc.||Biopsy anchor device with cutter|
|US6567689||Feb 27, 2002||May 20, 2003||Senorx, Inc.||Methods and chemical preparations for time-limited marking of biopsy sites|
|US6582713||Mar 30, 2001||Jun 24, 2003||Univ. Of Colorado - Colorado Springs||Compositions and methods for promoting wound healing|
|US6596293||May 17, 2000||Jul 22, 2003||Integra Lifesciences I, Ltd.||Polyurethane-biopolymer composite|
|US6630172||Jan 22, 2001||Oct 7, 2003||Kareem I. Batarseh||Microbicidal composition containing potassium sodium tartrate|
|US6638234||Nov 29, 2000||Oct 28, 2003||Senorx, Inc.||Sentinel node location and biopsy|
|US6662041||Oct 31, 2001||Dec 9, 2003||Senorx, Inc.||Imageable biopsy site marker|
|US6679851||Jun 12, 2001||Jan 20, 2004||Senorx, Inc.||Tissue accessing and anchoring device and method|
|US6692773||Jul 27, 2001||Feb 17, 2004||Nucryst Pharmaceuticals Corp.||Treatment of hyperproliferative skin disorders and diseases|
|US6716179||Jan 30, 2002||Apr 6, 2004||Senorx, Inc.||Sentinel node location and biopsy|
|US6716895||Dec 15, 1999||Apr 6, 2004||C.R. Bard, Inc.||Polymer compositions containing colloids of silver salts|
|US6719987||Apr 16, 2001||Apr 13, 2004||Nucryst Pharmaceuticals Corp.||Antimicrobial bioabsorbable materials|
|US6723350||Apr 23, 2002||Apr 20, 2004||Nucryst Pharmaceuticals Corp.||Lubricious coatings for substrates|
|US6725083||Nov 20, 2000||Apr 20, 2004||Senorx, Inc.||Tissue site markers for in VIVO imaging|
|US6758848||Jun 21, 2002||Jul 6, 2004||Senorx, Inc.||Apparatus and method for accessing a body site|
|US6861570||Mar 21, 2000||Mar 1, 2005||A. Bart Flick||Multilayer conductive appliance having wound healing and analgesic properties|
|US6862470||Apr 16, 2002||Mar 1, 2005||Senorx, Inc.||Cavity-filling biopsy site markers|
|US6875182||Apr 30, 2002||Apr 5, 2005||Senorx, Inc.||Electrosurgical specimen-collection system|
|US6916910||Nov 28, 2001||Jul 12, 2005||Bioscience Consultants||Method and process for the production of collagen preparations from invertebrate marine animals and compositions thereof|
|US6939566||Jan 17, 2001||Sep 6, 2005||Kareem I. Batarseh||Microbicidal formulations and methods to control microorganisms|
|US6939568||Apr 23, 2002||Sep 6, 2005||Nucryst Pharmaceuticals Corp.||Treatment of inflammatory skin conditions|
|US6989156||Apr 23, 2002||Jan 24, 2006||Nucryst Pharmaceuticals Corp.||Therapeutic treatments using the direct application of antimicrobial metal compositions|
|US6989157||Oct 22, 2002||Jan 24, 2006||Nucryst Pharmaceuticals Corp.||Dry powders of metal-containing compounds|
|US6993375||Apr 12, 2004||Jan 31, 2006||Senorx, Inc.||Tissue site markers for in vivo imaging|
|US6996433||Nov 21, 2003||Feb 7, 2006||Senorx, Inc.||Imageable biopsy site marker|
|US7001617||May 30, 2002||Feb 21, 2006||Nueryst Pharmaceuticals Corp.||Method of induction of apoptosis and inhibition of matrix metalloproteinases using antimicrobial metals|
|US7005556||Sep 3, 1996||Feb 28, 2006||Argentum Medical||Multilayer wound dressing|
|US7008647||Apr 23, 2001||Mar 7, 2006||Nucryst Pharmaceuticals Corp.||Treatment of acne|
|US7047063||Sep 10, 2003||May 16, 2006||Senorx, Inc.||Tissue site markers for in vivo imaging|
|US7078060||Feb 12, 2003||Jul 18, 2006||Nucryst Pharmaceuticals Corp.||Solutions and aerosols of metal-containing compounds|
|US7087249||Apr 23, 2002||Aug 8, 2006||Nucryst Pharmaceuticals Corp.||Treatment of mucosal membranes|
|US7137968||Mar 13, 2000||Nov 21, 2006||Nucryst Pharmaceuticals Corp.||Transcutaneous medical device dressings and method of use|
|US7179849||Aug 26, 2003||Feb 20, 2007||C. R. Bard, Inc.||Antimicrobial compositions containing colloids of oligodynamic metals|
|US7201925||Feb 2, 2004||Apr 10, 2007||Nueryst Pharmaceuticals Corp.||Treatment of ungual and subungual diseases|
|US7214847||Jul 11, 2000||May 8, 2007||Argentum Medical, L.L.C.||Multilayer conductive appliance having wound healing and analgesic properties|
|US7229439||May 21, 2004||Jun 12, 2007||Senorx, Inc.||Apparatus and method for accessing a body site|
|US7230153||Apr 29, 2005||Jun 12, 2007||Argentum International, Llc||Multilayer conductive appliance having wound healing and analgesic properties|
|US7255881||Oct 22, 2003||Aug 14, 2007||Nucryst Pharmaceuticals Corp.||Metal-containing materials|
|US7282034||Dec 5, 2003||Oct 16, 2007||Senorx, Inc.||Tissue accessing and anchoring device and method|
|US7291762||Sep 11, 2003||Nov 6, 2007||Argentum International, Llc||Multilayer conductive appliance having wound healing and analgesic properties|
|US7377902||Jan 23, 2002||May 27, 2008||Senorx, Inc.||Biopsy anchor device with cutter|
|US7427416||Oct 22, 2003||Sep 23, 2008||Nucryst Pharmaceuticals Corp.||Methods of treating conditions using metal-containing materials|
|US7470437||Nov 10, 2004||Dec 30, 2008||Nucryst Pharmaceuticals Corp.||Methods of treating conditions with a metal-containing material|
|US7565191||Jul 21, 2009||Senorx, Inc.||Tissue site markers for in vivo imaging|
|US7572236||Aug 3, 2006||Aug 11, 2009||Senorx, Inc.||Biopsy device with fluid delivery to tissue specimens|
|US7651505||Jan 26, 2010||Senorx, Inc.||Plugged tip delivery for marker placement|
|US7792569||Nov 16, 2004||Sep 7, 2010||Senorx, Inc.||Cavity-filling biopsy site markers|
|US7820284||Dec 3, 2002||Oct 26, 2010||C.R. Bard Inc.||Microbe-resistant medical device, microbe-resistant polymeric coating and methods for producing same|
|US7877133||Jan 25, 2011||Senorx, Inc.||Marker or filler forming fluid|
|US7970454||Jun 18, 2008||Jun 28, 2011||Senorx, Inc.||Marker delivery device with releasable plug|
|US7981051||Nov 5, 2008||Jul 19, 2011||Senorx, Inc.||Biopsy device with fluid delivery to tissue specimens|
|US7983734||May 23, 2003||Jul 19, 2011||Senorx, Inc.||Fibrous marker and intracorporeal delivery thereof|
|US7989674||Oct 30, 2007||Aug 2, 2011||Argentum Medical, Llc||Multilayer conductive appliance having wound healing and analgesic properties|
|US8034454||Oct 11, 2011||C.R. Bard, Inc.||Antimicrobial compositions containing colloids of oligodynamic metals|
|US8093444||May 7, 2007||Jan 10, 2012||Argentum Medical, Llc||Multilayer conductive appliance having wound healing and analgesic properties|
|US8118791||Oct 31, 2007||Feb 21, 2012||Argentum Medical, Llc||Medical device|
|US8147487||May 25, 2007||Apr 3, 2012||Senorx, Inc.||Apparatus and method for accessing a body site|
|US8157862||Dec 10, 2010||Apr 17, 2012||Senorx, Inc.||Tissue marking implant|
|US8177792||Nov 18, 2009||May 15, 2012||Senorx, Inc.||Plugged tip delivery tube for marker placement|
|US8219182||Jul 10, 2012||Senorx, Inc.||Cavity-filling biopsy site markers|
|US8224424||Jul 13, 2009||Jul 17, 2012||Senorx, Inc.||Tissue site markers for in vivo imaging|
|US8283513||Oct 9, 2012||Argentum Medical, Llc||Multilayer wound dressing|
|US8292822||Oct 23, 2012||Devicor Medical Products, Inc.||Biopsy localization method and device|
|US8293964||Oct 23, 2012||Argentum Medical, Llc||Multilayer laminate wound dressing|
|US8311610||Jan 22, 2009||Nov 13, 2012||C. R. Bard, Inc.||Biopsy tissue marker|
|US8317725||Nov 27, 2012||Senorx, Inc.||Biopsy device with fluid delivery to tissue specimens|
|US8343071||Oct 31, 2007||Jan 1, 2013||Senorx, Inc.||Biopsy device with aperture orientation and improved tip|
|US8360990||Jan 29, 2013||Senorx, Inc.||Biopsy device with aperture orientation and improved tip|
|US8361082||Mar 1, 2011||Jan 29, 2013||Senorx, Inc.||Marker delivery device with releasable plug|
|US8401622||Dec 17, 2007||Mar 19, 2013||C. R. Bard, Inc.||Biopsy marker with in situ-generated imaging properties|
|US8437834||May 7, 2013||C. R. Bard, Inc.||Breast marker|
|US8447386||Dec 14, 2010||May 21, 2013||Senorx, Inc.||Marker or filler forming fluid|
|US8449514||May 28, 2013||Argentum Medical, Llc||Conductive wound dressings and methods of use|
|US8455710||Apr 23, 2003||Jun 4, 2013||Argentum Medical, Llc||Conductive wound dressings and methods of use|
|US8486028||Sep 30, 2011||Jul 16, 2013||Bard Peripheral Vascular, Inc.||Tissue marking apparatus having drug-eluting tissue marker|
|US8498693||Apr 8, 2011||Jul 30, 2013||Senorx, Inc.||Intracorporeal marker and marker delivery device|
|US8579931||Sep 29, 2011||Nov 12, 2013||Bard Peripheral Vascular, Inc.||Apparatus for the percutaneous marking of a lesion|
|US8626269||Jun 8, 2011||Jan 7, 2014||Senorx, Inc.||Fibrous marker and intracorporeal delivery thereof|
|US8626270||Jun 13, 2012||Jan 7, 2014||Senorx, Inc.||Cavity-filling biopsy site markers|
|US8634899||Feb 3, 2006||Jan 21, 2014||Bard Peripheral Vascular, Inc.||Multi mode imaging marker|
|US8639315||May 16, 2013||Jan 28, 2014||Senorx, Inc.||Marker or filler forming fluid|
|US8641640||Oct 31, 2007||Feb 4, 2014||Senorx, Inc.||Tissue cutting member for a biopsy device|
|US8668737||Mar 21, 2012||Mar 11, 2014||Senorx, Inc.||Tissue marking implant|
|US8670818||Dec 30, 2008||Mar 11, 2014||C. R. Bard, Inc.||Marker delivery device for tissue marker placement|
|US8718745||May 25, 2010||May 6, 2014||Senorx, Inc.||Tissue site markers for in vivo imaging|
|US8784433||Apr 27, 2012||Jul 22, 2014||Senorx, Inc.||Plugged tip delivery tube for marker placement|
|US8801681||Oct 21, 2005||Aug 12, 2014||Argentum Medical, Llc||Medical device|
|US8865227||Dec 12, 2008||Oct 21, 2014||Smith & Nephew (Overseas) Limited||Metal carbonate particles and methods of making thereof|
|US8880154||Jul 19, 2013||Nov 4, 2014||Senorx, Inc.||Fibrous marker and intracorporeal delivery thereof|
|US8915864||Nov 21, 2012||Dec 23, 2014||Senorx, Inc.||Biopsy device with fluid delivery to tissue specimens|
|US8940684 *||Mar 15, 2013||Jan 27, 2015||Mimedx Group, Inc.||Cross-linked collagen comprising an antifungal agent|
|US8946163||Mar 15, 2013||Feb 3, 2015||Mimedx Group, Inc.||Cross-linked collagen comprising metallic anticancer agents|
|US8965486||Dec 6, 2013||Feb 24, 2015||Senorx, Inc.||Cavity filling biopsy site markers|
|US9039763||Jan 28, 2014||May 26, 2015||Senorx, Inc.||Tissue marking implant|
|US9042965||Mar 6, 2013||May 26, 2015||C. R. Bard, Inc.||Biopsy marker with in situ-generated imaging properties|
|US9044162||Jan 25, 2013||Jun 2, 2015||Senorx, Inc.||Marker delivery device with releasable plug|
|US9095325||May 22, 2006||Aug 4, 2015||Senorx, Inc.||Tissue cutting member for a biopsy device|
|US9149341||Nov 21, 2011||Oct 6, 2015||Senorx, Inc||Deployment of polysaccharide markers for treating a site within a patient|
|US9155799 *||Mar 15, 2013||Oct 13, 2015||Mimedx Group, Inc.||Cross-linked collagen with at least one bound antimicrobial agent for in vivo release of the agent|
|US9237937||Feb 20, 2015||Jan 19, 2016||Senorx, Inc.||Cavity-filling biopsy site markers|
|US9238090||Dec 24, 2014||Jan 19, 2016||Fettech, Llc||Tissue-based compositions|
|US9327061||Sep 21, 2009||May 3, 2016||Senorx, Inc.||Porous bioabsorbable implant|
|US9393261||Jul 22, 2011||Jul 19, 2016||Body Glide LLC||Antimicrobial anti-chafing chelated silver oxide compound|
|US9408592||Dec 16, 2004||Aug 9, 2016||Senorx, Inc.||Biopsy device with aperture orientation and improved tip|
|US20020058882 *||Nov 30, 2001||May 16, 2002||Artemis Medical, Incorporated||Biopsy localization method and device|
|US20020147154 *||Nov 28, 2001||Oct 10, 2002||Lloyd Wolfinbarger||Method and process for the production of collagen preparations from invertebrate marine animals and compositions thereof|
|US20030021854 *||Apr 23, 2002||Jan 30, 2003||Burrell Robert Edward||Method of induction of apoptosis and inhibition of matrix metalloproteinases using antimicrobial metals|
|US20030180378 *||Oct 22, 2002||Sep 25, 2003||Gillis Scott H.||Dry powders of metal-containing compounds|
|US20030203046 *||Feb 12, 2003||Oct 30, 2003||Burrell Robert E.||Solutions and aerosols of metal-containing compounds|
|US20030206966 *||Oct 22, 2002||Nov 6, 2003||Burrell Robert E.||Methods of inducing apoptosis and modulating metalloproteinases|
|US20030233101 *||Jun 17, 2002||Dec 18, 2003||Senorx, Inc.||Plugged tip delivery tube for marker placement|
|US20040049145 *||Sep 11, 2003||Mar 11, 2004||Flick A. Bart||Multilayer conductive appliance having wound healing and analgesic properties|
|US20040101479 *||Oct 10, 2003||May 27, 2004||Senorx, Inc.||Biopsy site marker and process and apparatus for applying it|
|US20040110738 *||Oct 22, 2003||Jun 10, 2004||Gillis Scott H.||Prophylactic treatment methods|
|US20040116551 *||Aug 26, 2003||Jun 17, 2004||Terry Richard N.||Antimicrobial compositions containing colloids of oligodynamic metals|
|US20040116806 *||Nov 21, 2003||Jun 17, 2004||Senorx, Inc.||Biopsy site marker and process and apparatus for applying it|
|US20040117652 *||Dec 5, 2003||Jun 17, 2004||Senorx, Inc.||Tissue accessing and anchoring device and method|
|US20040129112 *||Oct 22, 2003||Jul 8, 2004||Gillis Scott H.||Metal-containing materials|
|US20040131698 *||Oct 22, 2003||Jul 8, 2004||Gillis Scott H.||Methods of treating conditions using metal-containing materials|
|US20040176312 *||Feb 2, 2004||Sep 9, 2004||Gillis Scott H.||Treatment of ungual and subungual diseases|
|US20040191329 *||Oct 22, 2003||Sep 30, 2004||Burrell Robert E.||Compositions and methods of metal-containing materials|
|US20040193044 *||Apr 12, 2004||Sep 30, 2004||Senorx, Inc.||Tissue site markers for in vivo imaging|
|US20040236211 *||May 23, 2003||Nov 25, 2004||Senorx, Inc.||Marker or filler forming fluid|
|US20040236212 *||May 23, 2003||Nov 25, 2004||Senorx, Inc.||Fibrous marker and intracorporeal delivery thereof|
|US20040236213 *||Jan 7, 2004||Nov 25, 2004||Senorx, Inc.||Marker delivery device with releasable plug|
|US20050033195 *||Sep 16, 2004||Feb 10, 2005||Fulton Richard E.||Biopsy localization method and device|
|US20050045192 *||Sep 16, 2004||Mar 3, 2005||Artemis Medical, Inc.||Biopsy localization method and device|
|US20050063908 *||Sep 10, 2003||Mar 24, 2005||Senorx, Inc.||Tissue site markers for in vivo imaging|
|US20050119562 *||Oct 27, 2004||Jun 2, 2005||Senorx, Inc.||Fibrous marker formed of synthetic polymer strands|
|US20050143656 *||Nov 16, 2004||Jun 30, 2005||Senorx, Inc.||Cavity-filling biopsy site markers|
|US20050187489 *||Apr 4, 2005||Aug 25, 2005||Wardle John L.||Electrosurgical specimen-collection system|
|US20050197594 *||Apr 21, 2005||Sep 8, 2005||Senorx, Inc.||Tissue accessing and anchoring device and method|
|US20060083777 *||Nov 22, 2005||Apr 20, 2006||Nucryst Pharmaceuticals Corp.||Treatment of acne|
|US20060083792 *||Nov 22, 2005||Apr 20, 2006||Nucryst Pharmaceuticals Corp.||Therapeutic treatments using the direct application of antimicrobial metal compositions|
|US20060084865 *||Oct 25, 2005||Apr 20, 2006||Burbank Fred H||Imageable biopsy site marker|
|US20060122503 *||Jan 27, 2006||Jun 8, 2006||Senorx, Inc.||Imageable biopsy site marker|
|US20060155190 *||Mar 2, 2006||Jul 13, 2006||Senorx, Inc.||Imageable biopsy site marker|
|US20060173280 *||Feb 3, 2006||Aug 3, 2006||Inrad, Inc.||Multi Mode Imaging Marker|
|US20060204591 *||May 16, 2006||Sep 14, 2006||Nucryst Pharamaceuticals Corp., A Canadian Corporation||Treatment of mucosal membranes|
|US20060241411 *||Apr 20, 2005||Oct 26, 2006||Inrad, Inc.||Marking device with retracable cannula|
|US20070010778 *||Aug 24, 2006||Jan 11, 2007||Nucryst Pharmaceuticals Corp., A Canadian Corporation||Transcutaneous medical device dressings and method of use|
|US20070232955 *||May 25, 2007||Oct 4, 2007||Senorx, Inc.||Apparatus and method for accessing a body site|
|US20080014247 *||Jun 22, 2007||Jan 17, 2008||Nucryst Pharmaceuticals||Metal-containing formulations and methods of use|
|US20080014278 *||Jun 22, 2007||Jan 17, 2008||Nucryst Pharmaceuticals||Metal-containing formulations and methods of use|
|US20080014286 *||Aug 14, 2007||Jan 17, 2008||Nucryst Pharmaceuticals Corp., A Canada Corporation||Metal-containing materials|
|US20080039819 *||Jul 26, 2007||Feb 14, 2008||Senorx, Inc.||Marker formed of starch or other suitable polysaccharide|
|US20080044491 *||Jun 22, 2007||Feb 21, 2008||Nucryst Pharmaceuticals||Metal-containing formulations and methods of use|
|US20080050452 *||Jun 22, 2007||Feb 28, 2008||Nucryst Pharmaceuticals||Metal-containing formulations and methods of use|
|US20080058640 *||Oct 30, 2007||Mar 6, 2008||Senoxrx, Inc.||Marker formed of starch or other suitable polysaccharide|
|US20080254298 *||May 29, 2008||Oct 16, 2008||Meadwestvaco Corporation||Method for treating a substrate|
|US20090030309 *||Feb 21, 2008||Jan 29, 2009||Senorx, Inc.||Deployment of polysaccharide markers|
|US20090131825 *||Dec 18, 2008||May 21, 2009||Senorx, Inc.||Imageable biopsy site marker|
|US20090162448 *||Dec 12, 2008||Jun 25, 2009||Nucryst Pharmaceuticals Corp.||Metal Carbonate Particles and Methods of Making Thereof|
|US20090171198 *||Dec 19, 2008||Jul 2, 2009||Jones Michael L||Powdered marker|
|US20090287078 *||Jun 24, 2008||Nov 19, 2009||Senorx, Inc.||Marker or filler forming fluid|
|US20100010341 *||Dec 17, 2007||Jan 14, 2010||Talpade Dnyanesh A||Biopsy Marker with In Situ-Generated Imaging Properties|
|US20100010342 *||Jul 13, 2009||Jan 14, 2010||Senorx, Inc.||Tissue site markers for in vivo imaging|
|US20100030072 *||Dec 12, 2007||Feb 4, 2010||Casanova R Michael||Multiple Imaging Mode Tissue Marker|
|US20100082102 *||Apr 1, 2010||Senorx, Inc.||Porous bioabsorbable implant|
|US20100198059 *||Aug 5, 2010||Senorx, Inc.||Remotely activated marker|
|US20100298696 *||Aug 5, 2010||Nov 25, 2010||Bard Peripheral Vascular, Inc.||Self-contained, self-piercing, side-expelling marking apparatus|
|US20100298698 *||May 25, 2010||Nov 25, 2010||Senorx, Inc.||Tissue site markers for in vivo imaging|
|US20100324416 *||Aug 6, 2010||Dec 23, 2010||Senorx, Inc.||Cavity-filling biopsy site markers|
|US20100331668 *||Jan 22, 2009||Dec 30, 2010||Ranpura Himanshu M||Biopsy Tissue Marker|
|US20110028836 *||Dec 30, 2008||Feb 3, 2011||Himanshu Ranpura||Marker delivery device for tissue marker placement|
|US20110082547 *||Apr 7, 2011||Senorx, Inc.||Tissue marking implant|
|US20110092815 *||Dec 14, 2010||Apr 21, 2011||Senorx, Inc.||Marker or filler forming fluid|
|US20110166448 *||Jul 7, 2011||Jones Michael L||Marker delivery device with releasable plug|
|US20110184280 *||Jul 28, 2011||Jones Michael L||Intracorporeal marker and marker delivery device|
|US20110184449 *||Jul 28, 2011||Senorx, Inc.||Marker delivery device with obturator|
|USD715442||Sep 24, 2013||Oct 14, 2014||C. R. Bard, Inc.||Tissue marker for intracorporeal site identification|
|USD715942||Sep 24, 2013||Oct 21, 2014||C. R. Bard, Inc.||Tissue marker for intracorporeal site identification|
|USD716450||Sep 24, 2013||Oct 28, 2014||C. R. Bard, Inc.||Tissue marker for intracorporeal site identification|
|USD716451||Sep 24, 2013||Oct 28, 2014||C. R. Bard, Inc.||Tissue marker for intracorporeal site identification|
|CN104083804A *||Jun 23, 2014||Oct 8, 2014||福州市第二医院||Bone repair material and preparation method thereof|
|CN104083804B *||Jun 23, 2014||Mar 16, 2016||福州市第二医院||一种骨修复材料及其制备方法|
|EP0533809A1 *||Jun 14, 1991||Mar 31, 1993||Vitaphore Corp||Polyurethane-biopolymer composite.|
|EP0797965A1 *||Jun 14, 1991||Oct 1, 1997||Vitaphore Corporation||Wound dressing and catheter securing using a polyurethane-biopolymer composite|
|EP1120112A2 *||Jun 14, 1991||Aug 1, 2001||Integra LifeSciences Corporation||Wound dressing and drug delivery device|
|EP1525856A2||Jun 28, 2000||Apr 27, 2005||Senorx, Inc.||Apparatus for applying a biopsy site marker|
|EP1974686A2||Jun 28, 2000||Oct 1, 2008||Senorx, Inc.||Apparatus for applying a biopsy site marker|
|EP2277553A1||Jan 26, 2000||Jan 26, 2011||Senorx, Inc.||Preparations for time-limited marking of biopsy sites|
|WO1998031404A1 *||Jan 21, 1998||Jul 23, 1998||St. Jude Medical, Inc.||Medical article with adhered antimicrobial metal ions|
|WO2000045854A2 *||Jan 26, 2000||Aug 10, 2000||Senorx, Inc.||Preparations for time-limited marking of biopsy sites|
|WO2000045854A3 *||Jan 26, 2000||Apr 26, 2001||Senorx Inc||Preparations for time-limited marking of biopsy sites|
|U.S. Classification||422/24, 530/356, 106/157.6, 430/642, 204/157.68|
|International Classification||C08H1/06, A61L2/00, A61L27/54, A61K49/00, A61L2/18, A61F2/00, A61L27/24|
|Cooperative Classification||A61L2300/104, A61K49/006, A61L2/18, A61L2300/404, A61L27/54, A61L2/0088, C08H1/06, A61L27/24, A61F2310/00365|
|European Classification||A61L27/24, C08H1/06, A61L27/54, A61K49/00P8, A61L2/18, A61L2/00P4A|
|May 26, 1987||AS||Assignment|
Owner name: VITAPHORE CORPORATION, SAN CARLOS, CA, A CORP. OF
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:YAMAMOTO, RONALD;REEL/FRAME:004998/0088
Effective date: 19870327
|Jan 4, 1993||FPAY||Fee payment|
Year of fee payment: 4
|Nov 25, 1996||FPAY||Fee payment|
Year of fee payment: 8
|Jan 3, 2001||FPAY||Fee payment|
Year of fee payment: 12